Seizures clinical trials at UC Irvine

5 in progress, 4 open to eligible people

Showing trials for

  • XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)

    open to eligible people ages 18 years and up

    The X-TOLE3 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures.

    Orange 5379513, California 5332921 and other locations

  • EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome

    open to eligible people ages 2 years and up

    This is a multicenter, Phase 3, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of clemizole hydrochloride (EPX-100) as adjunctive therapy in children and adult participants with Dravet syndrome (DS).

    Orange 5379513, California 5332921 and other locations

  • XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

    open to eligible people ages 12 years and up

    This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of XEN1101 administered as adjunctive treatment in primary generalized tonic-clonic seizures (PGTCS).

    Orange 5379513, California 5332921 and other locations

  • FIH Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy

    open to eligible people ages 18-75

    This clinical trial is designed to test whether a single image-guided intracerebral administration of inhibitory nerve cells, called interneurons (NRTX-1001), into subjects with drug-resistant unilateral mesial temporal lobe epilepsy (MTLE), with or without mesial temporal sclerosis (MTS), is safe (frequency of adverse events) and effective (seizure frequency). NRTX-1001 comprises human interneurons that secrete a neurotransmitter, gamma-aminobutyric acid (GABA).

    Orange 5379513, California 5332921 and other locations

  • XEN1101 in Epilepsy

    Sorry, accepting new patients by invitation only

    This study will evaluate the long term safety, tolerability, pharmacokinetics (PK), and efficacy of XEN1101 in subjects with Focal Onset Seizures (FOS) or Primary Generalized Tonic-Clonic Seizures (PGTCS) for the treatment of seizures for up to 3 years.

    Orange 5379513, California 5332921 and other locations

Our lead scientists for Seizures research studies include .

Last updated: